Morgan Stanley Will Stop Offering New Access Investing Accounts
Morgan Stanley has announced that it will soon stop taking applications for new Access Investing accounts. The news was revealed this week in emails sent out to customers.
The bank is giving potential customers a chance to still open one of these accounts, with the last day being November 30th. Here’s the text of the email:
Morgan Stanley values you as a client and is committed to providing you with information related to your account(s).
Effective December 1, 2022, Access Investing® will no longer be offering the ability to open new accounts. This will have no impact to your existing account(s) and you may continue to fund your account(s). Rebalancing and ongoing maintenance of your account(s) will continue as well, and the ability to adjust your risk tolerance, time horizon and other goal parameters will remain available.
The Access Investing account is the cheapest option that makes you eligible for the Platinum Card from American Express exclusively for Morgan Stanley. This is a card that can get you yet another Platinum bonus, plus some other benefits that are not offered by other Platinum flavors:
- You can waive the $695 annual fee
- Add free Platinum authorized user card
- Cash out Membership Rewards at a value of 1 cent each
You can read more about the Platinum Card from American Express exclusively for Morgan Stanley here.
Conclusion
If you plan to apply for the Morgan Stanley Amex Platinum card, then check out the Access Investing account before it’s gone. However, now the main benefit is adding a free Platinum authorized user, and waiving the annual fee. However, the latter has become more costly, as you need to keep a balance in your account.
The cash out option at 1 cent value is also offered by the Amex Business Savings account, which is free.
 Chase Sapphire Preferred® Card
Chase Sapphire Preferred® Card is the old king of travel rewards cards. Right now bonus_miles_fullLearn more about this card and its features!
Opinions, reviews, analyses & recommendations are the author’s alone, and have not been reviewed, endorsed or approved by any of these entities.